DelveInsight has launched a new report on “Immune Thrombocytopenia – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Immune Thrombocytopenia – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Immune Thrombocytopenia, historical and forecasted epidemiology as well as the Immune Thrombocytopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Immune Thrombocytopenia Market Report:
According to DelveInsight’s analysis, there was a total of approximately 33,869 female and around 21,974 male diagnosed cases of ITP in 2020 in the United States.
In 2020, there were around 66,708 prevalent cases of ITP and approximately 55,844 diagnosed prevalent cases of ITP in the United States. Out of the total diagnosed cases, approximately 52,076 cases account for adult ITP and approximately 3,768 cases were diagnosed in the prevalence population of children in 2020 in the United States.
Key benefits of the report:
The Immune Thrombocytopenia market report covers a descriptive overview and comprehensive insight of the Immune Thrombocytopenia Epidemiology and Immune Thrombocytopenia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Immune Thrombocytopenia market report provides insights on the current and emerging therapies.
Immune Thrombocytopenia market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Immune Thrombocytopenia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Immune Thrombocytopenia market.
Immune Thrombocytopenia Overview
Immune thrombocytopenia (ITP), previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its own platelets and destroys them too quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function. Many of the symptoms of immune thrombocytopenia stem from a low platelet count leading to excessive bleeding.
Immune Thrombocytopenia Market
The dynamics of the Immune Thrombocytopenia market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Octapharma USA, Amgen, Dova Pharmaceuticals, Novartis, and others during the forecasted period 2018-2030.
Learn more by requesting for sample @ Immune Thrombocytopenia Market Landscape
Immune Thrombocytopenia Pipeline Therapies and Key Companies
Octagam: Octapharma USA
Nplate (AMG-531): Amgen
Doptelet (Avatrombopag): Dova Pharmaceuticals
Promacta (eltrombopag): Novartis, and others
Immune Thrombocytopenia Market Drivers
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Immune Thrombocytopenia Patient Share (%) Overview at a Glance
5. Immune Thrombocytopenia Market Overview at a Glance
6. Immune Thrombocytopenia Disease Background and Overview
7. Immune Thrombocytopenia Epidemiology and Patient Population
8. Country-Specific Patient Population of Immune Thrombocytopenia
9. Immune Thrombocytopenia Current Treatment and Medical Practices
10. Unmet Needs
11. Immune Thrombocytopenia Emerging Therapies
12. Immune Thrombocytopenia Market Outlook
13. Country-Wise Immune Thrombocytopenia Market Analysis (2018–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
18. Immune Thrombocytopenia Report Methodology
19. DelveInsight Capabilities
21. About DelveInsight
Click here to read more about Immune Thrombocytopenia Market Outlook 2030
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States